Essential oil of Gallesia integrifolia is active against mycobacteria

Papers of special note have been highlighted as: • of interest

References

• 1. Forbes BA. Mycobacterial taxonomy. J. Clin. Microbiol. 55(2), 380–383 (2017).
  MedlineGoogle Scholar
• 2. World Health Organization. Global Tuberculosis Report (2020). https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf (Accessed 3 June 2022).
  Google Scholar
• 3. World Health Organization. Global Tuberculosis Report (2021). www.who.int/publications/digital/global-tuberculosis-report-2021/tb-disease-burden (Accessed 5 June 2022).
  Google Scholar
• 4. Jakasania A, Shringarpure K, Kapadia D et al. Side effects-part of the package: a mixed methods approach to study adverse events among patients being programmatically treated for DR-TB in Gujarat, India. BMC Infect. Dis. 20(1), 1–12 (2020).
  Google Scholar
• 5. Tortoli E. Microbiological features and clinical relevance of new species of the genus Mycobacterium. Clin. Microbiol. Rev. 27(4), 727–752 (2014).
  Medline CASGoogle Scholar
• 6. Saxena S, Spaink HP, Forn-Cuní G. Drug resistance in nontuberculous mycobacteria: mechanisms and models. Biology (Basel) 10(2), 96 (2021).
  Medline CASGoogle Scholar
• 7. Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J. Thorac. Dis. 6(3), 210–220 (2014).
  MedlineGoogle Scholar
• 8. Gygli SM, Borrell S, Trauner A et al. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. FEMS Microbiol. Rev. 41(3), 354–373 (2017).
  Medline CASGoogle Scholar
• 9. Nasiri MJ, Haeili M, Ghazi M et al. New insights in to the intrinsic and acquired drug resistance mechanisms in mycobacteria. Front. Microbiol. 8(1), 681 (2017).
  MedlineGoogle Scholar
• 10. Pereira SG, Alarico S, Tiago I et al. Studies of antimicrobial resistance in rare mycobacteria from a nosocomial environment. BMC Microbiol. 19(1), 1–12 (2019).
  Medline CASGoogle Scholar
• 11. Coronado-Aceves EW, Sánchez-Escalante JJ, López-Cervantes J et al. Antimycobacterial activity of medicinal plants used by the Mayo people of Sonora, Mexico. J. Ethnopharmacol. 190(1), 106–115 (2016).
  MedlineGoogle Scholar
• 12. Gupta VK, Kumar MM, Bisht D et al. Plants in our combating strategies against Mycobacterium tuberculosis: progress made and obstacles met. Pharm. Biol. 55(1), 1536–1544 (2017).
  MedlineGoogle Scholar
• 13. Gupta VK, Kaushik A, Chauhan DS et al. Anti-mycobacterial activity of some medicinal plants used traditionally by tribes from Madhya Pradesh, India for treating tuberculosis related symptoms. J. Ethnopharmacol. 227(1), 113–120 (2018). • Describes composition, ethnopharmacological use and activity of extracts of Gallesia integrifolia.
  MedlineGoogle Scholar
• 14. Arunachalam K, Ascêncio SD, Soares IM et al. Gallesia integrifolia (Spreng.) Harms: in vitro and in vivo antibacterial activities and mode of action. J. Ethnopharmacol. 184(1), 128–137 (2016).
  MedlineGoogle Scholar
• 15. Raimundo KF, Bortolucci WC, Glamočlija J et al. Antifungal activity of Gallesia integrifolia fruit essential oil. Braz. J. Microbiol. 49(1), 229–235 (2018).
  Medline CASGoogle Scholar
• 16. Raimundo KF, Bortolucci WC, Silva ES et al. Chemical composition of garlic wood (Gallesia integrifolia) (Phytolaccaceae) volatile compounds and their activity on cattle tick. Aust. J. Crop Sci. 11(8), 1058–1067 (2017). • Describes the resazurin microtiter assay plate.
  CASGoogle Scholar
• 17. Palomino J-C, Martin A, Camacho M et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46(8), 2720–2722 (2002).
  Medline CASGoogle Scholar
• 18. Scodro RBL, Pires CTA, Carrara VS et al. Anti-tuberculosis neolignans from Piper regnellii. Phytomedicine 20(7), 600–604 (2013).
  Medline CASGoogle Scholar
• 19. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, Nocardia, and other aerobic Actinomycetes; approved standard – Second Edition. 2, 1–249 (2011). • Describes the resazurin drugs combination microtiter assay.
  Google Scholar
• 20. Caleffi-Ferracioli KR, Maltempe FG, Siqueira VLD et al. Fast detection of drug interaction in Mycobacterium tuberculosis by a checkerboard resazurin method. Tuberculosis 93(6), 660–663 (2013).
  Medline CASGoogle Scholar
• 21. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52(1), 1 (2003). • Describes the hemolysis assay.
  Medline CASGoogle Scholar
• 22. Sampiron EG, Costacurta GF, Baldin VP et al. Hydrazone, benzohydrazones and isoniazid-acylhydrazones as potential antituberculosis agents. Future Microbiol. 14(11), 981–994 (2019). • Describes the cytotoxicity assay.
  CASGoogle Scholar
• 23. Valverde TL, Sampiron EG, Montaholi DC et al. 3,5-Dinitrobenzoylhydrazone derivatives as a scaffold for antituberculosis drug development. Future Microbiol. 17(4), 267–280 (2022).
  CASGoogle Scholar
• 24. Arunachalam K, Balogun SO, Pavan EA et al. Chemical characterization, toxicology and mechanism of gastric antiulcer action of essential oil from Gallesia integrifolia (Spreng.) Harms in the in vitro and in vivo experimental models. Biomed. Pharmacother. 94(1), 292–306 (2017).
  Medline CASGoogle Scholar
• 25. Baldin VP, Scodro RBL, Fernandez M et al. Ginger essential oil and fractions against Mycobacterium spp. J. Ethnopharmacol. 244(1), 112095 (2019).
  Medline CASGoogle Scholar
• 26. Hegeto LA, Caleffi-Ferracioli KR, Nakamura-Vasconcelos SS et al. In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis. Tuberculosis 111(1), 35–40 (2018).
  Medline CASGoogle Scholar
• 27. Basaraba RJ, Hunter RL. Pathology of tuberculosis: how the pathology of human tuberculosis informs and directs animal models. Microbiol. Spectr. 5(3), 1–13 (2017).
  Google Scholar
• 28. Baldwin SL, Larsenid SE, Ordway D et al. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Negl. Trop. Dis. 13(3), 1–23 (2019).
  Google Scholar
• 29. Pang Y, Zheng H, Tan Y et al. In vitro activity of bedaquiline against nontuberculous mycobacteria in China. Antimicrob. Agents Chemother. 61(5), e02627–16 (2017).
  Medline CASGoogle Scholar
• 30. Peruč D, Gobin I, Abram M et al. Antimycobacterial potential of the juniper berry essential oil in tap water. Arh. Hig. Rada Toksikol. 69(1), 46–54 (2018).
  MedlineGoogle Scholar
• 31. Bueno J, Escobar P, Martínez JR et al. Composition of three essential oils, and their mammalian cell toxicity and antimycobacterial activity against drug resistant-tuberculosis and nontuberculous mycobacteria strains. Nat. Prod. Commun. 6(11), 1743–1748 (2011).
  Medline CASGoogle Scholar
• 32. Pavan FR, Maia PIS, Leite SRA et al. Thiosemicarbazones, semicarbazones, dithiocarbazates and hydrazide/hydrazones: Anti-Mycobacterium tuberculosis activity and cytotoxicity. Eur. J. Med. Chem. 45(5), 1898–1905 (2010).
  Medline CASGoogle Scholar
• 33. Rapido F. The potential adverse effects of haemolysis. Blood Transfus. 15(8), 218–221 (2017).
  MedlineGoogle Scholar
• 34. Vo NNQ, Fukushima EO, Muranaka T. Structure and hemolytic activity relationships of triterpenoid saponins and sapogenins. J. Nat. Med. 71(1), 50–58 (2017).
  Medline CASGoogle Scholar
• 35. Feng M, Tang B, Liang SH et al. Sulfur containing scaffolds in drugs: synthesis and application in medicinal chemistry. Curr. Top Med. Chem. 16(11), 1200–1216 (2016).
  Medline CASGoogle Scholar